研报掘金｜中金：大幅上调药明巨诺目标价至6.04港元 维持“跑赢行业”评级
JW THERAPJW THERAP(HK:02126) Ge Long Hui·2025-09-04 03:22

Core Viewpoint - CICC's research report indicates that WuXi AppTec's revenue for the first half of the year reached 106 million yuan, representing a year-on-year increase of 22.5%, with better-than-expected loss reduction [1] Group 1 - CICC maintains an "outperforming the industry" rating for WuXi AppTec, considering the company's loss reduction, progress in SLE and early pipeline, along with the upward adjustment of industry valuation [1] - The target price for WuXi AppTec has been raised by 151.7% to 6.04 HKD [1]